With $22M B round, OncoCell to launch prostate cancer test

With its $22.2 million series B round, OncoCell plans to launch next summer the first blood test from its diagnostic platform based on immune gene expression profiles.

Mark

Read the full 271 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE